Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' Free Cash Flow fell 10.83% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 32.83%. This contributed to the annual value of -$197.0 million for FY2024, which is 0.45% up from last year.
  • Inhibrx Biosciences' Free Cash Flow amounted to -$33.8 million in Q3 2025, which was down 12.96% from -$30.0 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Free Cash Flow ranged from a high of -$30.0 million in Q2 2025 and a low of -$64.2 million during Q1 2024.
  • In the last 3 years, Inhibrx Biosciences' Free Cash Flow had a median value of -$43.7 million in 2024 and averaged -$45.8 million.
  • The largest annual percentage gain for Inhibrx Biosciences' Free Cash Flow in the last 5 years was 48.86% (2025), contrasted with its biggest fall of 10.83% (2025).
  • Inhibrx Biosciences' Free Cash Flow (Quarterly) stood at -$60.3 million in 2023, then grew by 27.42% to -$43.7 million in 2024, then fell by 10.83% to -$33.8 million in 2025.
  • Its Free Cash Flow stands at -$33.8 million for Q3 2025, versus -$30.0 million for Q2 2025 and -$35.9 million for Q1 2025.